Significance of thromboembolic phenomena occurring before and during chemoradiotherapy for localized carcinoma of the esophagus and gastroesophageal junction

Diseases of the Esophagus

Volumn 21, Issue 7, 2008, Pages 575-581

  Tetzlaff, E D ^a   Correa, A M ^a   Komaki, R ^a   Swisher, S G ^a   Maru, D ^a   Ross, W A ^a   Ajani, J A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Gastroesophageal cancer chemotherapy; Prognosis; Radiotherapy; Survival; Thrombosis

Indexed keywords

CISPLATIN; D DIMER; DOCETAXEL; FLUOROURACIL; IRINOTECAN; OXALIPLATIN; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER MORTALITY; CANCER PATIENT; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURGERY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; DISEASE DURATION; ECHOGRAPHY; ESOPHAGOGASTRODUODENOSCOPY; ESOPHAGUS CARCINOMA; FEMALE; GASTROESOPHAGEAL CANCER; HUMAN; LOWER ESOPHAGUS SPHINCTER; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; THROMBOEMBOLISM; VEIN THROMBOSIS;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; FEMALE; HUMANS; MALE; MIDDLE AGED; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; SURVIVAL RATE; THROMBOEMBOLISM;

EID: 53149092890     PISSN: 11208694     EISSN: 14422050     Source Type: Journal    
DOI: 10.1111/j.1442-2050.2008.00829.x     Document Type: Article

References (13)

1. Levitan N, Dowlati A, Remick S et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy: The risk analysis using Medicare claims data. Medicine 1999; 78 (5): 285-91.
2. Sorensen H, Mellemkjaer L, Steffensen F, Olsen J, Nielson G. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolis. N Engl J Med 1998; 338: 1169-73.
3. Sorensen H, Mellemkjaer L, Olsen J, Baron J. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000; 343: 1846-50.
4. Furie B, Furie B C. Cancer-associated thrombosis. Blood Cells Mol Dis 2006; 36: 177-81.
5. Tetzlaff E D, Correa A M, Baker J, Ensor J, Ajani J A. The impact on survival of thromboembolic phenomena occurring before and during protocol chemotherapy in patients with advanced gastroesophageal cancer. Cancer 2007; 109 (10): 1989-95.
6. Green F L, Page D L, Fleming I D et al. AJCC Cancer Staging Manual, 6th edn. New York: Springer-Verlag, 2002; 91-8.
7. National Cancer Institute Website. Available at: http://ctep.cancer.gov/ reporting-/ctc.html. Accessed on November 13, 2006.
8. Klerk C P, Smorenburg S M, Otten H M et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005; 23: 2130-5.
9. Alcalay H, Wun T, Khatri V et al. Venous thromboembolis in patients with colorectal cancer: Incidence and effect on survival. J Clin Oncol 2006; 24: 1112-8.
10. Lee A, Rickles F, Julian J et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the surivial of patients with cancer and venous thromboembolism. J Clin Oncol 2005; 23: 2123-9.
11. Kakkar A, Levine M, Kadziola Z et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: The fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 2004; 22: 1944-8.
12. Palareti G, Cosmi B, Legnani C et al. D-dimer testing to determine duration of anticoagulation therapy. N Engl J Med 2006; 355: 1780-9.
13. Storto M L, Di Credico A, Guido F, Larici A R, Bonomo L. Incidental detection of pulmonary emboli on routine MDCT of the chest. AJR Am J Roentgenol 2005; 184: 264-7.